BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Islam R, Kar S, Islam C, Farmen R. Adaptation of commercial biomarker kits and proposal for ‘drug development kits’ to support bioanalysis: call for action. Bioanalysis 2018;10:945-55. [DOI: 10.4155/bio-2017-0254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Piccoli SP, Garofolo F. Biomarker assay validation. Bioanalysis 2018;10:889-91. [DOI: 10.4155/bio-2018-0127] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
2 Islam R, Kar S, Ritzén H, Hays A, Tayyem R, Barry C, Keyhani A, Zimmer J, Cruz Caturla M, Couerbe P, Warren M, Khadang A, Bourdage J, Lindley K, Williams D, Hughes N, Sheldon C, Satterwhite C, Vija J, Yu M, Boulay I, Stamatopoulos J, Lin J, Cape S, Estdale S, Thomas E, Dinan A, Macneill R, Xiao YQ, Garofolo W, Savoie N, Brown M, Rhyne P, Hristopoulos G, Xu A, Goodwin L, Spriggs F, Xu A, Awaiye K, Hayes R, St Charles J, Bouhajib M, Dimarco C, Dimarco L, Savu SR, Bennett P, Kakkanaiah V, Nehls C, Stouffer B, Tabler E, Briscoe C, Karnik S, Dubey I, Kulagina N, Lindsay J, Beaver C, Williard C, Wang H, Feng H, Malone M, Wells E, Fang X, Moussallie M. Recommendations for classification of commercial LBA kits for biomarkers in drug development from the GCC for bioanalysis. Bioanalysis 2019;11:645-53. [DOI: 10.4155/bio-2019-0072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Dolman A, Yu X, Gusev AI. Data driven CRO benchmarking for biomarker analysis. Bioanalysis 2020;12:1117-27. [PMID: 32885989 DOI: 10.4155/bio-2020-0164] [Reference Citation Analysis]